Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD). 

• The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization (WHO) drinking risk levels.
• Opiant is developing OPNT002 to rapidly increase plasma concentrations of the drug following dosing and thereby block mu and delta-opioid receptors. 
• Also See: Opiant Pharma Stock Surges On Positive Nasal Nalmefene Data In Opioid Overdose Study
• In previous research, OPNT002 has demonstrated rapid nasal absorption, delivering high levels of naltrexone yet with a short half-life. Results from Phase 1 studies indicate that OPNT002 produces maximum plasma concentrations that are approximately 50% higher than orally administered naltrexone.
• The trial will enroll approximately 300 patients and feature a Sequential Parallel Comparison Study Design (SPCD) to reduce placebo response. 
• Results from the trial are expected in 2023.
• Price Action: OPNT shares closed 2.89% lower at $25.52 on Thursday.